Overview of Dr. Drullinsky
Dr. Pamela Drullinsky is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, Phelps Memorial Hospital Center, and St. Catherine of Siena Hospital. She received her medical degree from Tel Aviv University Sackler and has been in practice 26 years. She is one of 497 doctors at Memorial Sloan Kettering Cancer Center and one of 19 doctors at Phelps Memorial Hospital Center who specialize in Oncology. She also speaks multiple languages, including Spanish. She has more than 30 publications and over 500 citings.
Office
1919 Madison Avenue
(Entrance on 124th Street)
New York, NY 10035
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1994 - 1997
Tel Aviv University SacklerClass of 1991
Certifications & Licensure
FL State Medical License 2022 - Present
NJ State Medical License 1997 - 2025
NY State Medical License 1992 - 2025- American Board of Internal Medicine Medical Oncology
Clinical Trials
Publications & Presentations
PubMed
- 137 citationsAlpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre...Hope S Rugo, Florence Lerebours, Eva Ciruelos, Pamela Drullinsky, Manuel Ruiz-Borrego
The Lancet. Oncology. 2024-12-01 - 1 citationsto: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.Zachary D Epstein-Peterson, Esther Drill, Umut Aypar, Connie Lee Batlevi, Philip Caron
Haematologica. 2024-08-01 - 1 citationsImmunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.Zachary D Epstein-Peterson, Esther Drill, Umut Aypar, Connie Lee Batlevi, Philip Caron
Haematologica. 2024-04-01
Abstracts/Posters
- A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell LymphomaPamela Drullinsky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin LymphomaPamela Drullinsky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
